TriVascular2: A New Beginning
Boston Scientific agreed to divest itself of its TriVascular abdominal aortic aneurysm company, selling it for $65 million to MPM Capital, New Enterprise Associates, Kearny Venture Partners and Delphi Ventures.
Boston Scientific agreed to divest itself of its TriVascular abdominal aortic aneurysm company, selling it for $65 million to MPM Capital, New Enterprise Associates, Kearny Venture Partners and Delphi Ventures.